In this article, we will discuss Olaparib (Description-18). So, let’s get started.
Clinical Studies (2)
A total of 391 patients were randomized, 260 to Olaparib and 131 to placebo. The median age of patients treated with Olaparib was 53 years (range: 29 to 82) and 53 years (range: 31 to 84) among patients on placebo. The ECOG performance status (PS) was 0 in 77% of patients receiving Olaparib and 80% of
patients receiving placebo. Of all patients, 82% were White, 36% were enrolled in the U.S. or Canada, and 82% were in complete response to their most recent platinum-based regimen. The majority of patients (n=389) had germline BRCA mutation (gBRCAm), and 2 patients had somatic BRCAm (sBRCAm).